Switch theme
Sign up to access all valuation multiples
LigaChem Biosciences Inc develops new drugs through research. The Company provides business research services, manufacturing and sale of compounds, and drug evaluation.
2006
n/a
LTM Revenue $110M
LTM EBITDA $10.1M
$2.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
LigaChem Biosciences has a last 12-month revenue of $110M and a last 12-month EBITDA of $10.1M.
In the most recent fiscal year, LigaChem Biosciences achieved revenue of $85.8M and an EBITDA of $10.0M.
LigaChem Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See LigaChem Biosciences valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $23.3M | $85.8M | XXX | XXX | XXX |
| Gross Profit | $12.2M | $12.1M | XXX | XXX | XXX |
| Gross Margin | 52% | 14% | XXX | XXX | XXX |
| EBITDA | -$48.1M | $10.0M | XXX | XXX | XXX |
| EBITDA Margin | -207% | 12% | XXX | XXX | XXX |
| Net Profit | -$30.7M | -$50.2M | XXX | XXX | XXX |
| Net Margin | -132% | -59% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, LigaChem Biosciences's stock price is KRW 110900 (or $76).
LigaChem Biosciences has current market cap of KRW 4.02T (or $2.7B), and EV of KRW 3.53T (or $2.4B).
See LigaChem Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.4B | $2.7B | XXX | XXX | XXX | XXX | $0.57 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, LigaChem Biosciences has market cap of $2.7B and EV of $2.4B.
LigaChem Biosciences's trades at 21.8x LTM EV/Revenue multiple, and 238.7x LTM EBITDA.
Analysts estimate LigaChem Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for LigaChem Biosciences and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.4B | XXX | XXX | XXX |
| EV/Revenue | 28.0x | XXX | XXX | XXX |
| EV/EBITDA | 241.2x | XXX | XXX | XXX |
| P/E | 515.8x | XXX | XXX | XXX |
| P/E/Growth | 2.8x | XXX | XXX | XXX |
| EV/FCF | 48.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpLigaChem Biosciences's NTM/LTM revenue growth is 57%
LigaChem Biosciences's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, LigaChem Biosciences's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate LigaChem Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for LigaChem Biosciences and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 269% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -121% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 68% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 90% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 104% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
LigaChem Biosciences acquired XXX companies to date.
Last acquisition by LigaChem Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . LigaChem Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was LigaChem Biosciences founded? | LigaChem Biosciences was founded in 2006. |
| Where is LigaChem Biosciences headquartered? | LigaChem Biosciences is headquartered in South Korea. |
| Who is the CEO of LigaChem Biosciences? | LigaChem Biosciences's CEO is Mr. Yong-Ju Kim. |
| Is LigaChem Biosciences publicy listed? | Yes, LigaChem Biosciences is a public company listed on KRX. |
| What is the stock symbol of LigaChem Biosciences? | LigaChem Biosciences trades under 141080 ticker. |
| When did LigaChem Biosciences go public? | LigaChem Biosciences went public in 2013. |
| Who are competitors of LigaChem Biosciences? | Similar companies to LigaChem Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of LigaChem Biosciences? | LigaChem Biosciences's current market cap is $2.7B |
| What is the current revenue of LigaChem Biosciences? | LigaChem Biosciences's last 12-month revenue is $110M. |
| What is the current EBITDA of LigaChem Biosciences? | LigaChem Biosciences's last 12-month EBITDA is $10.1M. |
| What is the current EV/Revenue multiple of LigaChem Biosciences? | Current revenue multiple of LigaChem Biosciences is 21.8x. |
| What is the current EV/EBITDA multiple of LigaChem Biosciences? | Current EBITDA multiple of LigaChem Biosciences is 238.7x. |
| What is the current revenue growth of LigaChem Biosciences? | LigaChem Biosciences revenue growth between 2023 and 2024 was 269%. |
| Is LigaChem Biosciences profitable? | Yes, LigaChem Biosciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
